Welcome to our dedicated page for iRhythm Holdings news (Ticker: IRTC), a resource for investors and traders seeking the latest updates and insights on iRhythm Holdings stock.
iRhythm Technologies, Inc. (NASDAQ: IRTC) generates frequent news as a digital health care company focused on long-term ambulatory cardiac monitoring and data-driven arrhythmia detection. News coverage commonly highlights clinical study results, financial performance, product-related updates for the Zio long-term continuous monitoring (LTCM) service, and the company’s participation in major medical and investor conferences.
Many announcements center on real-world evidence and clinical research. iRhythm regularly reports data from large-scale analyses and trials such as CAMELOT, AVALON, AMALFI, and studies presented at the American Heart Association Scientific Sessions, the Asia Pacific Heart Rhythm Society meetings, and other scientific forums. These updates often explore topics like diagnostic yield compared with other monitoring modalities, performance in diverse patient populations, home-based self-application of Zio devices, and earlier arrhythmia detection in at-risk groups, including those with cardio-kidney-metabolic or chronic kidney disease profiles.
Investors and clinicians following IRTC news will also find quarterly earnings releases, guidance updates, and commentary on operational trends in the company’s core Zio LTCM business, mobile cardiac telemetry initiatives, and international expansion. Additional items include information on investor presentations at healthcare conferences and updates on corporate policies or governance disclosed through press releases linked to SEC filings.
This news page aggregates these developments in one place, allowing readers to review iRhythm’s latest clinical evidence, business updates, and strategic commentary over time. For those tracking digital health, ambulatory ECG monitoring, and AI-enabled cardiac diagnostics, the IRTC news feed provides ongoing insight into how the company presents its technology, research findings, and market priorities.
iRhythm Technologies (NASDAQ: IRTC) has announced the pricing of an underwritten public offering of 1,093,167 shares at $175.00 per share, aiming to raise approximately $191.3 million. The offering includes a 30-day option for underwriters to purchase an additional 163,975 shares. The funds will support growth initiatives, working capital, and potential expansions, such as enhancing their sales force and increasing R&D activities. The offering is set to close on August 21, 2020, pending customary conditions.
iRhythm Technologies, Inc. (NASDAQ: IRTC) has initiated a public offering of 1,000,000 shares of common stock, with an option for underwriters to purchase an additional 150,000 shares. The proceeds will fund growth initiatives, expand the sales force and operations, enhance R&D activities, and support general corporate purposes. The offering is subject to market conditions, and there are no current agreements for acquisitions. The registration statement has been filed with the SEC but is not yet effective.
iRhythm Technologies, Inc. (NASDAQ: IRTC) reported a 3% decline in revenue for Q2 2020, totaling $50.9 million, compared to $52.4 million in Q2 2019. Gross margin decreased to 69.6% from 75.2% year-over-year, with operating expenses rising 11.1% to $55.6 million. The net loss widened to $20.4 million or $0.75 per share, versus a loss of $10.7 million or $0.43 per share in the prior year. The company has not provided full-year guidance due to ongoing COVID-19 uncertainties.
iRhythm Technologies (NASDAQ: IRTC) is set to host a conference call on August 4, 2020, at 1:10 PM PT to discuss the impact of new Medicare codes on its business, as outlined in the 2021 Medicare Physician Fee Schedule Proposed Rule. The event will be available via live and archived webcast on the company’s investor website. iRhythm specializes in digital health care solutions for diagnosing cardiac arrhythmias, using advanced biosensor devices and proprietary algorithms.
iRhythm Technologies is set to present at the 40th Annual Canaccord Genuity Global Growth Conference on August 13, 2020, at 11:30 a.m. ET in Boston, MA. The company specializes in digital health solutions for cardiac care, utilizing wearable biosensor devices and advanced cloud-based analytics for arrhythmia diagnosis. Interested participants can access the live and archived webcast through the company's website. This conference represents a significant opportunity for iRhythm to showcase its innovative approaches to cardiac health diagnostics.
iRhythm Technologies (NASDAQ: IRTC) has announced it will release its Q2 2020 financial results after market close on August 6, 2020. The management team will conduct a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Investors can access the call via a live and archived webcast on the company’s website.
iRhythm is recognized for its innovative approach to cardiac care, utilizing wearable biosensors and cloud-based analytics to enhance arrhythmia detection.
Summary not available.